In the test cohort, HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH levels were elevated in glioma tissues with high-risk scores (Figure 6G). This evidence concerns the gene PTPN2 and central nervous system cancer.